127 related articles for article (PubMed ID: 7537518)
1. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
2. Structural analyses of human thymidylate synthase reveal a site that may control conformational switching between active and inactive states.
Chen D; Jansson A; Sim D; Larsson A; Nordlund P
J Biol Chem; 2017 Aug; 292(32):13449-13458. PubMed ID: 28634233
[TBL] [Abstract][Full Text] [Related]
3. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
Kager L; Cheok M; Yang W; Zaza G; Cheng Q; Panetta JC; Pui CH; Downing JR; Relling MV; Evans WE
J Clin Invest; 2005 Jan; 115(1):110-7. PubMed ID: 15630450
[TBL] [Abstract][Full Text] [Related]
4. A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.
Marverti G; Gozzi G; Maretti E; Lauriola A; Severi L; Sacchetti F; Losi L; Pacifico S; Ferrari S; Ponterini G; Leo E; Costi MP; D'Arca D
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585842
[TBL] [Abstract][Full Text] [Related]
5. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
Wilson PM; Danenberg PV; Johnston PG; Lenz HJ; Ladner RD
Nat Rev Clin Oncol; 2014 May; 11(5):282-98. PubMed ID: 24732946
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil.
Vinod BS; Antony J; Nair HH; Puliyappadamba VT; Saikia M; Narayanan SS; Bevin A; Anto RJ
Cell Death Dis; 2013 Feb; 4(2):e505. PubMed ID: 23429291
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy.
Ahn MJ; Choi JH; Oh HS; Lee YY; Kim IS; Choi IY; Lee KH; Song KW; Park CK
Cancer Res Treat; 2005 Aug; 37(4):216-22. PubMed ID: 19956517
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).
Gangjee A; Jain HD; Phan J; Lin X; Song X; McGuire JJ; Kisliuk RL
J Med Chem; 2006 Feb; 49(3):1055-65. PubMed ID: 16451071
[TBL] [Abstract][Full Text] [Related]
9. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.
Walling J
Invest New Drugs; 2006 Jan; 24(1):37-77. PubMed ID: 16380836
[No Abstract] [Full Text] [Related]
10. A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies.
Benepal T; Jackman A; Pyle L; Bate S; Hardcastle A; Aherne W; Mitchell F; Simmons L; Ruddle R; Raynaud F; Gore M
Br J Cancer; 2005 Oct; 93(8):868-75. PubMed ID: 16222320
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
[TBL] [Abstract][Full Text] [Related]
12. Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells.
Wang W; Cassidy J
Br J Cancer; 2003 Feb; 88(4):624-9. PubMed ID: 12592379
[TBL] [Abstract][Full Text] [Related]
13. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
Webley SD; Hardcastle A; Ladner RD; Jackman AL; Aherne GW
Br J Cancer; 2000 Sep; 83(6):792-9. PubMed ID: 10952785
[TBL] [Abstract][Full Text] [Related]
14. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
[TBL] [Abstract][Full Text] [Related]
15. Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex.
Orlandi L; Bearzatto A; Abolafio G; De Marco C; Daidone MG; Zaffaroni N
Br J Cancer; 1999 Sep; 81(2):252-60. PubMed ID: 10496350
[TBL] [Abstract][Full Text] [Related]
16. A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus.
Skelton LA; Ormerod MG; Titley J; Kimbell R; Brunton LA; Jackman AL
Br J Cancer; 1999 Apr; 79(11-12):1692-701. PubMed ID: 10206279
[TBL] [Abstract][Full Text] [Related]
17. Tumour markers of prognosis in colorectal cancer.
McLeod HL; Murray GI
Br J Cancer; 1999 Jan; 79(2):191-203. PubMed ID: 9888457
[No Abstract] [Full Text] [Related]
18. The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.
Walton MI; Mitchell F; Aherne GW; Medlow CJ; Boyle FT; Jackman AL
Br J Cancer; 1998 Dec; 78(11):1457-63. PubMed ID: 9836478
[TBL] [Abstract][Full Text] [Related]
19. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
20. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
Aherne GW; Ward E; Lawrence N; Dobinson D; Clarke SJ; Musgrove H; Sutcliffe F; Stephens T; Jackman AL
Br J Cancer; 1998; 77(2):221-6. PubMed ID: 9460992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
